To read the full story, subscribe or sign in.

Nextcure stock drops near 30% on $745M ADC deal with Simcere

June 17, 2025

Shares of Nextcure Inc. (NASDAQ:NXTC) dropped 26.27% on news of a potential $745 million partnership with Simcere Zaiming for Simcere’s cadherin-6 antibody-drug conjugate (ADC) candidate. Shares ended at 50 cents apiece June 16.

BioWorld BioWorld Asia Deals and M&A Deals and M&A Cancer Antibody-drug conjugate Asia-Pacific China U.S. FDA

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...